Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab

被引：17

作者：

Sutton, Rosemary ^{[1
,2
]}

Dalla Pozza, Luciano ^{[3
]}

Khaw, Seong Lin ^{[4
]}

Fraser, Chris ^{[5
]}

Revesz, Tom ^{[6
,7
]}

Chamberlain, Janis ^{[8
]}

Mitchell, Richard ^{[2
,9
]}

Trahair, Toby N. ^{[1
,2
,9
]}

Bateman, Caroline M. ^{[3
]}

Venn, Nicola C. ^{[1
]}

Law, Tamara ^{[1
]}

Ong, Erika ^{[1
]}

Heatley, Susan L. ^{[7
,10
]}

McClure, Barbara J. ^{[7
,10
]}

Meyer, Claus ^{[11
]}

Marschalek, Rolf ^{[11
]}

Henderson, Michelle J. ^{[1
,2
]}

Cross, Siobhan ^{[12
]}

White, Deborah L. ^{[7
,10
,13
]}

Kotecha, Rishi S. ^{[14
,15
,16
]}

机构：

[1] Childrens Canc Inst, Mol Diagnost, Sydney, NSW, Australia

[2] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia

[3] Childrens Hosp Westmead, Canc Ctr Children, Sydney, NSW, Australia

[4] Royal Childrens Hosp, Childrens Canc Ctr, Melbourne, Vic, Australia

[5] Queensland Childrens Hosp, Blood & Bone Marrow Transplant Program, Brisbane, Qld, Australia

[6] Womens & Childrens Hosp, Dept Clin Haematol & Oncol, Adelaide, SA, Australia

[7] Univ Adelaide, Adelaide, SA, Australia

[8] John Hunter Childrens Hosp, Newcastle, NSW, Australia

[9] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia

[10] South Australian Hlth & Med Res Inst, Precis Med Theme, Adelaide, SA, Australia

[11] Goethe Univ, Inst Pharmaceut Biol, Diagnost Ctr Acute Leukemia, Frankfurt, Germany

[12] Christchurch Hosp, Childrens Haematol Oncol Ctr, Christchurch, New Zealand

[13] Australian Genom Hlth Alliance, Melbourne, Vic, Australia

[14] Perth Childrens Hosp, Dept Clin Haematol Oncol & Bone Marrow Transplant, Perth, WA, Australia

[15] Univ Western Australia, Telethon Kids Canc Ctr, Telethon Kids Inst, Perth, WA, Australia

[16] Curtin Univ, Sch Pharm & Biomed Sci, Perth, WA, Australia

来源：

PEDIATRIC BLOOD & CANCER | 2021年 / 68卷 / 05期

基金：

英国医学研究理事会;

关键词：

acute lymphoblastic leukaemia; blinatumomab; paediatric; refractory; relapse; MINIMAL RESIDUAL DISEASE; PEDIATRIC-PATIENTS; RELAPSE;

D O I：

10.1002/pbc.28922

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.

引用

页数：7

共 50 条

[1] Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
Hathaway, Lindsey
Sen, Jeremy Michael
Keng, Michael
PATIENT-RELATED OUTCOME MEASURES, 2018, 9 : 329 - 337
[2] Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin
Cassaday, Ryan D.
Marks, David I.
DeAngelo, Daniel J.
Jabbour, Elias J.
Advani, Anjali S.
O'Brien, Susan
Wang, Tao
Neuhof, Alexander
Vandendries, Erik
Kantarjian, Hagop M.
Stock, Wendy
Stelljes, Matthias
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (03) : E77 - E81
[3] Importance of blinatumomab in relapsed or refractory acute lymphoblastic leukemia B
Machet, Antoine
Gallego-Hernanz, Pilar
Torregrosa-Diaz, Jose
Leleu, Xavier
HEMATOLOGIE, 2016, 22 (01): : 17 - 18
[4] The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia
Benjamin, Jonathan E.
Stein, Anthony S.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (03) : 142 - 156
[5] Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
Topp, Max S.
Goekbuget, Nicola
Zugmaier, Gerhard
Stein, Anthony S.
Dombret, Herve
Chen, Yuqi
Ribera, Josep-Maria
Bargou, Ralf C.
Horst, Heinz-August
Kantarjian, Hagop M.
CANCER, 2021, 127 (04) : 554 - 559
[6] Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome
Meyr, Franziska
Escherich, Gabriele
Mann, Georg
Klingebiel, Thomas
Kulozik, Andreas
Rossig, Claudia
Schrappe, Martin
Henze, Guenter
von Stackelberg, Arend
Hitzler, Johann
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (01) : 98 - 106
[7] Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
Kantarjian, Hagop M.
Logan, Aaron C.
Zaman, Faraz
Goekbuget, Nicola
Bargou, Ralf C.
Zeng, Yi
Zugmaier, Gerhard
Locatelli, Franco
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2023, 14
[8] Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
Topp, Max S.
Zimmerman, Zachary
Cannell, Paul
Dombret, Herve
Maertens, Johan
Stein, Anthony
Franklin, Janet
Qui Tran
Cong, Ze
Schuh, Andre C.
BLOOD, 2018, 131 (26) : 2906 - 2914
[9] French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia
Trioche, Pascale
Nelken, Brigitte
Michel, Gerard
Pellier, Isabelle
Petit, Arnaud
Bertrand, Yves
Rohrlich, Pierre
Schmitt, Claudine
Sirvent, Nicolas
Boutard, Patrick
Margueritte, Genevieve
Pautard, Brigitte
Ducassou, Stephane
Plantaz, Dominique
Robert, Alain
Thomas, Caroline
Desseaux, Kristell
Chevret, Sylvie
Baruchel, Andre
EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2012, 1
[10] Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy
Kuchimanchi, Mita
Zhu, Min
Clements, John D.
Doshi, Sameer
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (04) : 807 - 817

← 1 2 3 4 5 →